 |
 |

Mandatory HPV VaccinationPublic Health vs Private Wealth
Lawrence O. Gostin, JD, LLD;
Catherine D. DeAngelis, MD, MPH
JAMA. 2007;297:1921-1923.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
By any measure, genital human papillomavirus (HPV) infection and HPV-associated cervical cancer are significant national and global public health concerns. An estimated 11 000 newly diagnosed cases of cervical cancer occur annually in the United States, resulting in 3700 deaths.1 Globally, an estimated 493 000 new cervical cancer cases occur each year, with 274 000 deaths; more than 80% of cervical cancer deaths worldwide occur in developing countries.2
Human papillomavirus is the most common sexually transmitted infection in the United States, with an estimated 6.2 million individuals newly infected annually.3 Data from the National Health and Nutrition Examination Survey revealed a 26.8% overall HPV prevalence among US girls and women, with increasing prevalence each year for ages 14 to 24 years (44.8% for ages 20-24 years) followed by a gradual decline in prevalence through age 59 years (19.6% for ages 50-59 years).4 Although . . . [Full Text of this Article]
Author Affiliations: Georgetown Law Center, Washington, DC (Dr Gostin). Dr DeAngelis is Editor in Chief, JAMA.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Human papillomavirus vaccination programmes
Lo
BMJ 2007;335:357-358.
FULL TEXT
In This Issue: Clinical Diagnosis and Management
Stange
Ann Fam Med 2007;5:290-291.
FULL TEXT
JAMA's Contributing Writers
DeAngelis and Fontanarosa
JAMA 2007;297:2139-2140.
FULL TEXT
|